Business Description
Sorrento Therapeutics Inc
NAICS : 325414
SIC : 8731
ISIN : US83587F2020
Description
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.03 | |||||
9-Day RSI | 0.84 | |||||
14-Day RSI | 3.25 | |||||
3-1 Month Momentum % | -83.87 | |||||
6-1 Month Momentum % | -91.8 | |||||
12-1 Month Momentum % | -28.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -378.42 | |||||
OCF Margin % | -365.06 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-Forward-EBIT | 1.57 | |||||
EV-to-Forward-Revenue | 3.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sorrento Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 64.27 | ||
| EPS (TTM) ($) | -1.12 | ||
| Beta | 0.4096 | ||
| 3-Year Sharpe Ratio | 0.27 | ||
| 3-Year Sortino Ratio | 1.16 | ||
| Volatility % | 791.48 | ||
| 14-Day RSI | 3.25 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 0.0005 | ||
| 12-1 Month Momentum % | -28.57 | ||
| 52-Week Range ($) | 0.0005 - 0.0071 | ||
| Shares Outstanding (Mil) | 551.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sorrento Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sorrento Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 36 days | ||
| General meeting for 2025 | 2026-07-14 | In 6 days | ||
| First quarter earnings results for 2026 | 2026-07-07 | 0.00 (+0.00%) |
Show
Entries
Sorrento Therapeutics Inc Frequently Asked Questions
What is Sorrento Therapeutics Inc(LTS:0L85)'s stock price today?
The current price of LTS:0L85 is $0.00. The 52 week high of LTS:0L85 is $0.01 and 52 week low is $0.00.
When is next earnings date of Sorrento Therapeutics Inc(LTS:0L85)?
The next earnings date of Sorrento Therapeutics Inc(LTS:0L85) is 2026-07-14 Est..
Does Sorrento Therapeutics Inc(LTS:0L85) pay dividends? If so, how much?
Sorrento Therapeutics Inc(LTS:0L85) does not pay dividend.
Press Release
Articles on Sorrento Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers